VU University Medical Center

Amsterdam NL1081

0 studies enrolling now · 37 studies all time

What they study most

Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Advanced Breast Cancer, Advanced Unresectable Pancreatic Cancer, Aggressive B-cell Non-Hodgkin Lymphoma (aNHL), Anaesthesia, Angina, Stable, Angina, Unstable, B-cell Chronic Lymphocytic Leukemia, Breast Cancer, Breast Cancer Female, Breast Neoplasm

Studies at this site

• A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer — Running, not enrolling
• First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma — Running, not enrolling
• Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer — Running, not enrolling
• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma — Running, not enrolling
• Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) — Completed
• Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma — Completed
• HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy — Running, not enrolling
• Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia — Stopped early
• An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) — Completed
• REDUCE LAP-HF TRIAL II — Running, not enrolling
• Selinexor (KPT-330) in Older Patients With Relapsed AML — Completed
• G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer — Completed
• Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 — Stopped early
• New International CTEPH Database — Completed
• Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery — Completed
• Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008 — Completed
• Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria — Stopped early
• Physiologic Assessment of Coronary Stenosis Following PCI — Completed
• A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy — Completed
• Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis — Completed
• Clinical Evaluation of Metal Panel Allergens: Dose Response Study — Completed
• Computed TomogRaphic Evaluation of Atherosclerotic DEtermiNants of Myocardial IsChEmia — Completed
• Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Selonsertib in Adults With Pulmonary Arterial Hypertension — Completed
• A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease — Completed
• Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias — Completed
• A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease — Completed
• The Safety And Efficacy Of Maintenance Therapy With CP-690,550 — Completed
• American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis — Status unconfirmed
• Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer — Stopped early
• Local Assessment of Ventilatory Management During General Anesthesia for Surgery — Completed
• MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction — Stopped early
• Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA) — Status unconfirmed
• GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer — Stopped early